Page 1,963«..1020..1,9621,9631,9641,965..1,9701,980..»

Nasal cells help paralyzed man make history by walking

Posted: October 23, 2014 at 7:48 am

A man paralyzed from the chest down in a knife attack is walking again as a result of undergoing surgery using cells responsible for the sense of smell, marking an advance in the search for treatments for spinal injuries.

Darek Fidyka, 38, received the cells after failing to recover from a stabbing in the back in 2010, according to University College London, whose doctors developed the procedure. The technique involves using olfactory ensheathing cells and placing them in the spinal cord.

The study gives hope to the thousands of people each year who suffer a severe spinal cord injury and must live the rest of their lives with permanently damaged body functions. Such injuries typically occur during sports or automobile crashes and there is no approved treatment to repair them.

We have now opened the door to a treatment of spinal cord injury that will get patients out of wheelchairs, said Geoffrey Raisman, chairman of neural regeneration at the UCL Institute of Neurology and leader of the British research team. Our goal now is to develop this first procedure to a point where it can be rolled out as a worldwide general approach.

The cells used were discovered by Raisman in 1985 and were shown to work in treating spinal injuries in rats in 1997. They allow nerve cells that give people their sense of smell to grow back when they are damaged. The procedure on Fidyka was performed by surgeons at Wroclaw University Hospital in Poland.

For the treatment, Fidyka underwent brain surgery to remove an olfactory bulb, a structure responsible for the sense of smell. The bulb was placed in a cell culture for two weeks to produce olfactory cells, which were injected into the spinal cord along with four strips of nerve tissue taken from the ankle. The strips formed bridges for the spinal nerve fibers to grow across, with the aid of the cells.

Three months after the surgery, Fidyka's left thigh muscle began to grow and after six months he was starting to walk within the rehabilitation center with the help of a physiotherapist and leg braces, according to UCL. His bladder sensation and sexual function have improved.

This technology has been confined to labs, so it's promising to see that it may have helped someone recover from a clean cut through the spinal cord, said Jeremy Fairbank, a professor of spine surgery at the University of Oxford who wasn't involved in the research.

The next question is what sort of clinical experiments must be done to prove that this works, Fairbank said. I suspect it will take years until there is a practical way of doing this.

The research, funded by Britain's Stem Cell Foundation and the Nicholls Spinal Injury Foundation, was published in the Cell Transplantation journal. Further studies in patients are planned by UCL and Wroclaw University Hospital, according to Michael Hanna, director of the UCL Institute of Neurology.

See the rest here:
Nasal cells help paralyzed man make history by walking

Posted in Colorado Stem Cells | Comments Off on Nasal cells help paralyzed man make history by walking

More than 900 Physicians Converge on Buenos Aires for Global Stem Cells Groups First International Symposium on Stem …

Posted: October 23, 2014 at 7:42 am

MIAMI (PRWEB) October 22, 2014

More than 900 physicians researchers and regenerative medicine experts from around the world attended the First International Symposium on Stem Cells and Regenerative Medicine, held in Buenos Aires, Argentina Oct. 2-4, 2014.

The event, hosted by Global Stem Cells Group in partnership with Julio Ferreira, M.D., President of the South American Academy Cosmetic Surgery, offered an opportunity for many of the worlds most respected authorities on stem cell and regenerative medicine to showcase advancements in research and therapies on a global level.

An interdisciplinary team of leading international stem cell experts provided a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine who served as featured speakers at the event included:

Lord David Harrell, PhD., a scientific leader recognized nationally, internationally recognized expert in neuroscience and regenerative medicine and a member of the Global Stem Cells Group Advisory Board spoke on spoke on the cellular composition of bone marrow with a focus on stem and progenitor cell activities of bone marrow stem and progenitor cells.

Joseph Purita, M.D., Director of The Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, member of the Global Stem Cells Group Advisory Board and a pioneer in the use of stem cells and platelet rich plasma for a variety of orthopedic conditions, spoke about the use of PRP and stem cell injections for treatment of musculoskeletal conditions. He detailed cutting-edge treatments he now offers to his clinic patients, including extensive use of platelet-rich plasma in conjunction with bone marrow stem cells (BMAC), adipose stem cells (SVF) and fat grafts.

Vasilis Paspaliaris, M.D., CEO of Adistem, Ltd., a member of the Global Stem Cells Group Advisory Board and a thought-leading and highly experienced clinical pharmacologist and medical scientist discussed the proven differences in efficacy between the mesenchyme stem cells (MSCs) of a young donor and those of an aging donor, primarily due to the younger donor cells ability to secrete more trophic factors.

According to Benito Novas, Global Stem Cells Group CEO, the world-class event was well received at a time when the field of regenerative medicine is on the verge of changing medical science forever.

We wanted the symposium to help clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing, Novas says. We set out to establish a dialogue between researchers and practitioners in order to help move stem cell therapies from the lab to the physicians office and I believe we achieved our goals with this symposium.

Our objective is to open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices.

Continued here:
More than 900 Physicians Converge on Buenos Aires for Global Stem Cells Groups First International Symposium on Stem ...

Posted in Regenerative Medicine | Comments Off on More than 900 Physicians Converge on Buenos Aires for Global Stem Cells Groups First International Symposium on Stem …

NYSCF Research Institute announces largest-ever stem cell repository

Posted: October 23, 2014 at 7:40 am

15 hours ago

The New York Stem Cell Foundation (NYSCF) Research Institute, through the launch of its repository in 2015, will provide for the first time the largest-ever number of stem cell lines available to the scientific research community. Initially, over 600 induced pluripotent stem (iPS) cell lines and 1,000 cultured fibroblasts from over 1,000 unique human subjects will be made available, with an increasing number available in the first year. To collect these samples, NYSCF set up a rigorous human subjects system that protects patients and allows for the safe and anonymous collection of samples from people interested in participating in research.

A pilot of over 200 of NYSCF's iPS cell lines is already searchable on an online database. The pilot includes panels of iPS cell lines generated from donors affected by specific diseases such as type 1 diabetes, Parkinson's disease, and multiple sclerosis, as well as a diversity panel of presumed healthy donors from a wide range of genetic backgrounds representing the United States Census. These panels, curated to provide ideal initial cohorts for studying each area, include subjects ranging in age of disease onset, and are gender matched. Other panels that will be available in 2015 include Alzheimer's disease, schizophrenia, Juvenile Batten disease, and Charcot-Marie-Tooth disease.

"NYSCF's mission is to develop new treatments for patients. Building the necessary infrastructure and making resources available to scientists around the world to further everyone's research are critical steps in accomplishing this goal," said Susan L. Solomon, CEO of The New York Stem Cell Foundation.

NYSCF has developed the technology needed to create a large collection of stem cell lines representing the world's population. This platform, known as the NYSCF Global Stem Cell ArrayTM, is an automated robotic system for stem cell production and is capable of generating 200 iPS cell lines a month from patients with various diseases and conditions and from all genetic backgrounds. The NYSCF Global Stem Cell ArrayTM is also used for stem cell differentiation and drug screening.

Currently available in the online database that was developed in collaboration with eagle-i Network, of the Harvard Catalyst, is a pilot set of approximately 200 iPS cell lines and related information about the patients. This open source, open access resource discovery platform makes the cell lines and related information available to the public on a user-friendly, web-based, searchable system. This is one example of NYSCF's efforts to reduce duplicative research and enable even broader collaborative research efforts via data sharing and analysis. NYSCF continues to play a key role in connecting the dots between patients, scientists, funders, and outside researchers that all need access to biological samples.

"The NYSCF repository will be a critical complement to other existing efforts which are limited in their ability to distribute on a global scale. I believe that this NYSCF effort wholly supported by philanthropy will help accelerate the use of iPS cell based technology," said Dr. Mahendra Rao, NYSCF Vice President of Regenerative Medicine.

To develop these resources, NYSCF has partnered with over 50 disease foundations, academic institutions, pharmaceutical companies, and government entities, including the Parkinson's Progression Markers Initiative (PPMI), PersonalGenomes.org, the Beyond Batten Disease Foundation, among several others. NYSCF also participates in and drives a number of large-scale multi stakeholder initiatives including government and international efforts. One such example is the Cure Alzheimer's Fund Stem Cell Consortium, a group consisting of six institutions, including NYSCF, directly investigating, for the first time, brain cells in petri dishes from individual patients who have the common sporadic form of Alzheimer's disease.

"We are entering this next important phase of using stem cells to understand disease and discover new drugs. Having collaborated with NYSCF extensively over the last five years on the automation of stem cell production and differentiation, it's really an exciting moment to see these new technologies that NYSCF has developed now being made available to the entire academic and commercial research communities," said Dr. Kevin Eggan, Professor of Stem Cell and Regenerative Biology at Harvard University and Principal Investigator of the Harvard Stem Cell Institute.

NYSCF's unique technological resources have resulted in partnerships with companies to develop both stem cell lines and also collaborative research programs. Over the past year, NYSCF has established collaborations with four pharmaceutical companies to accelerate the translation of basic scientific discoveries into the clinic. Federal and state governments are also working with NYSCF to further stem cell research in the pursuit of cures. In 2013, NYSCF partnered with the National Institutes of Health (NIH) Undiagnosed Disease Program (UDP) to generate stem cell lines from 100 patients in the UDP and also collaborate with UDP researchers to better understand and potentially treat select rare diseases.

More here:
NYSCF Research Institute announces largest-ever stem cell repository

Posted in Stem Cell Therapy | Comments Off on NYSCF Research Institute announces largest-ever stem cell repository

Many Elderly Found with Puzzling Mutations Linked to Leukemia, Lymphoma

Posted: October 23, 2014 at 2:45 am

Health and Medicine for Seniors

Many Elderly Found with Puzzling Mutations Linked to Leukemia, Lymphoma

Researchers find no connection with blood cancer that seldom strikes senior citizens

Oct. 22, 2014 A surprisingly large percentage 5 percent of senior citizens over age 70 have been found to have genetic mutations linked to leukemia and lymphoma in their blood cells. The vast majority won't get blood cancer, however, as the incidence of these cancers is less than 0.1 percent among the elderly, according to the researchers at Washington University School of Medicine in St. Louis.

Mutations in the body's cells randomly accumulate as part of the aging process, and most are harmless. For some people, genetic changes in blood cells can develop in genes that play roles in initiating leukemia and lymphoma even though such people don't have the blood cancers, the scientists reported Oct. 19 in Nature Medicine.

"But it's quite striking how many people over age 70 have these mutations," said senior author Li Ding, PhD, of The Genome Institute at Washington University. "The power of this study lies in the large number of people we screened. We don't yet know whether having one of these mutations causes a higher than normal risk of developing blood cancers. More research would be required to better understand that risk."

The researchers analyzed blood samples from 3,000 people enrolled in The Cancer Genome Atlas project, a massive endeavor funded by the National Cancer Institute and the National Human Genome Research Institute at the National Institutes of Health (NIH). The effort involves cataloguing the genetic errors involved in more than 20 types of cancers.

The patients whose blood was analyzed for the current study had been diagnosed with cancer but were not known to have leukemia, lymphoma or a blood disease.

They ranged in age from 10 to 90 at the time of diagnosis and had donated blood and tumor samples before starting cancer treatment. Therefore, any mutations identified by the researchers would not have been associated with chemotherapy or radiation therapy, which can damage cells' DNA.

The researchers, including Genome Institute scientists Mingchao Xie, Charles Lu, PhD, and Jiayin Wang, PhD, zeroed in on mutations that were present in the blood but not in tumor samples from the same patients. Such genetic changes in the blood would be associated with changes in stem cells that develop into blood cells, but not to the same patient's cancer.

Read more here:
Many Elderly Found with Puzzling Mutations Linked to Leukemia, Lymphoma

Posted in Genetic medicine | Comments Off on Many Elderly Found with Puzzling Mutations Linked to Leukemia, Lymphoma

The New York Stem Cell Foundation Research Institute announces largest-ever stem cell repository

Posted: October 23, 2014 at 2:43 am

PUBLIC RELEASE DATE:

22-Oct-2014

Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation @nyscf

NEW YORK, NY (October 22, 2014) The New York Stem Cell Foundation (NYSCF) Research Institute, through the launch of its repository in 2015, will provide for the first time the largest-ever number of stem cell lines available to the scientific research community. Initially, over 600 induced pluripotent stem (iPS) cell lines and 1,000 cultured fibroblasts from over 1,000 unique human subjects will be made available, with an increasing number available in the first year. To collect these samples, NYSCF set up a rigorous human subjects system that protects patients and allows for the safe and anonymous collection of samples from people interested in participating in research.

A pilot of over 200 of NYSCF's iPS cell lines is already searchable on an online database. The pilot includes panels of iPS cell lines generated from donors affected by specific diseases such as type 1 diabetes, Parkinson's disease, and multiple sclerosis, as well as a diversity panel of presumed healthy donors from a wide range of genetic backgrounds representing the United States Census. These panels, curated to provide ideal initial cohorts for studying each area, include subjects ranging in age of disease onset, and are gender matched. Other panels that will be available in 2015 include Alzheimer's disease, schizophrenia, Juvenile Batten disease, and Charcot-Marie-Tooth disease.

"NYSCF's mission is to develop new treatments for patients. Building the necessary infrastructure and making resources available to scientists around the world to further everyone's research are critical steps in accomplishing this goal," said Susan L. Solomon, CEO of The New York Stem Cell Foundation.

NYSCF has developed the technology needed to create a large collection of stem cell lines representing the world's population. This platform, known as the NYSCF Global Stem Cell ArrayTM, is an automated robotic system for stem cell production and is capable of generating 200 iPS cell lines a month from patients with various diseases and conditions and from all genetic backgrounds. The NYSCF Global Stem Cell ArrayTM is also used for stem cell differentiation and drug screening.

Currently available in the online database that was developed in collaboration with eagle-i Network, of the Harvard Catalyst, is a pilot set of approximately 200 iPS cell lines and related information about the patients. This open source, open access resource discovery platform makes the cell lines and related information available to the public on a user-friendly, web-based, searchable system. This is one example of NYSCF's efforts to reduce duplicative research and enable even broader collaborative research efforts via data sharing and analysis. NYSCF continues to play a key role in connecting the dots between patients, scientists, funders, and outside researchers that all need access to biological samples.

"The NYSCF repository will be a critical complement to other existing efforts which are limited in their ability to distribute on a global scale. I believe that this NYSCF effort wholly supported by philanthropy will help accelerate the use of iPS cell based technology," said Dr. Mahendra Rao, NYSCF Vice President of Regenerative Medicine.

To develop these resources, NYSCF has partnered with over 50 disease foundations, academic institutions, pharmaceutical companies, and government entities, including the Parkinson's Progression Markers Initiative (PPMI), PersonalGenomes.org, the Beyond Batten Disease Foundation, among several others. NYSCF also participates in and drives a number of large-scale multi stakeholder initiatives including government and international efforts. One such example is the Cure Alzheimer's Fund Stem Cell Consortium, a group consisting of six institutions, including NYSCF, directly investigating, for the first time, brain cells in petri dishes from individual patients who have the common sporadic form of Alzheimer's disease.

See original here:
The New York Stem Cell Foundation Research Institute announces largest-ever stem cell repository

Posted in Cell Medicine | Comments Off on The New York Stem Cell Foundation Research Institute announces largest-ever stem cell repository

University Of Pennsylvania's T-Cell Therapy Shows Promising Results

Posted: October 23, 2014 at 2:42 am

By C. Rajan, contributing writer

The University of Pennsylvania has announced promising results of its novel chimeric antigen receptor (CAR) therapy for cancer.

In the study involving 25 children and five adults with end-stage acute lymphoblastic leukemia (ALL), there was an impressive 90 percent response rate with complete remission.

Twenty-seven of the 30 patients went into complete remission after receiving the investigational therapy (called CTL019), and 78 percent of the patients were alive six months after treatment. The longest remission among the patients has lasted almost three years.

The patients who participated in these trials had relapsed as many as four times, including 60 percent whose cancers came back even after stem cell transplants. Their cancers were so aggressive they had no treatment options left, said the studys senior author, Stephan Grupp, MD, PhD, at the Children's Hospital of Philadelphia. The durable responses we have observed with CTL019 therapy are unprecedented.

The ongoing study is being conducted by researchers at the Childrens Hospital of Philadelphia and the Hospital of the University of Pennsylvania (Penn). The CAR trial program enrolling children with leukemia is also expanding to nine other pediatric centers.

The experimental CAR therapy received FDAs breakthrough designation in July for the treatment of relapsed and refractory adult and pediatric ALL. The novel treatment was pioneered by Penn researchers and then supported by Novartis. Penn entered an exclusive global research and licensing agreement with Novartis in 2012 to develop and commercialize personalized CAR T-cell therapies for cancers.

"This represents a really powerful therapy for ALL," Penn oncologist David Porter says. "We've treated enough patients to confirm that. It's time to start multi-center trials."

A CAR is a genetically engineered marker protein that is grafted onto T cells, which are part of the immune system. The CAR activates the T cell to attack tumor cells that express specific markers; in this case, the target is a protein called CD19.

The treatment procedure involves removing patients' T cells via an apheresis process and then genetically reprogramming them to hunt tumor cells. When injected back into patients bodies, these new hunter cells multiply and attack tumor cells expressing CD19. The hunter cells can grow, creating 10,000+ new cells in the body for each single engineered cell injected into the patients.

Visit link:
University Of Pennsylvania's T-Cell Therapy Shows Promising Results

Posted in Cell Therapy | Comments Off on University Of Pennsylvania's T-Cell Therapy Shows Promising Results

Bone Marrow-Derived Stem Cell Prolotherapy – Video

Posted: October 22, 2014 at 9:40 pm


Bone Marrow-Derived Stem Cell Prolotherapy
Stem Cell Prolotherapy is a procedure in which adult mesenchymal stem cells are transplanted directly into the damaged tissue or injury and promotes healing. Stem cells are the repairmen...

By: Kab S. Hong M.D.

See original here:
Bone Marrow-Derived Stem Cell Prolotherapy - Video

Posted in Stem Cell Videos | Comments Off on Bone Marrow-Derived Stem Cell Prolotherapy – Video

Do I Need PRP/PRF/PDGF/BMP For Dental Implants and Bone grafts? – Video

Posted: October 22, 2014 at 9:40 pm


Do I Need PRP/PRF/PDGF/BMP For Dental Implants and Bone grafts?
http://www.burbankdentalimplants.com/blog/ In this video, I described what is PRP and PRF and how to concentrate growth factors, stem cells and molecular enhancers made from your own blood...

By: Ramsey Amin

Original post:
Do I Need PRP/PRF/PDGF/BMP For Dental Implants and Bone grafts? - Video

Posted in Stem Cell Videos | Comments Off on Do I Need PRP/PRF/PDGF/BMP For Dental Implants and Bone grafts? – Video

Stem Cell Research to Make Man Walk Again – Video

Posted: October 22, 2014 at 9:40 pm


Stem Cell Research to Make Man Walk Again
New science stem cell research to have succes to make man walk again thru reconecting disconected nerves in-between the spinal cord with stem cells from the ...

By: ZoodyZoe

Continue reading here:
Stem Cell Research to Make Man Walk Again - Video

Posted in Stem Cell Research | Comments Off on Stem Cell Research to Make Man Walk Again – Video

Maritza Novas, R.N., M.S.N and Alfredo Hoyos, M.D. to Speak at the EuroMedicom Aesthetic & Anti-Aging Medicine World …

Posted: October 22, 2014 at 12:47 pm

Miami, FL (PRWEB) October 21, 2014

Global Stem Cells Group has announced that Alfredo Hoyos, M.D. and Maritza Novas, R.N., M.S.N. will be speaking at the EuroMedicom First AMWC Latin America Aesthetic & Anti-aging Medicine World Congress in Medellin, Colombia, Nov. 27, 28 and 29, 2014.

The World Congress Colombia event is organized in cooperation with the International Scientific Board of the AMWC Monaco event, the largest international event in the field of aesthetic and anti-aging medicine. The goal of the event is to showcase the AMWCs commitment to innovation, expertise and excellence in aesthetic and anti-aging medicine, and to share a wealth of experience and teaching skills with attendees from around the world.

In addition to keeping up with worldwide practices, the Medellin conference is designed to contribute to enhancing practitioners skills through advanced academic and clinical sessions, as well as lectures presented by prominent experts in the field like Hoyos and Novas.

Novas and Hoyos will discuss the latest advancements in stem cell medicine for cosmetic and anti-aging applications. Hoyos, founder of Stem Lab, Global Stem Cells Group's new representative in Colombia, will also discuss plans to hold a symposium on stem cell and regenerative medicine in Bogota in Feb., 2014.

Novas is a lead trainer and part of the research and development team for Stem Cell Training, a Global Stem Cells Group subsidiary. Hoyos, a prominent Colombian plastic surgeon, is the world-renowned creator of high-definition liposculpture and other advanced body contour techniques. Hoyos will also be promoting the new collaboration between Global Stem Cells Group and his Colombia-based Stem Lab biotechnology company, which develops stem cell techniques for regenerative medicine treatments.

Hoyos serves Global Stem Cells Group and its subsidiary Regenestem as exclusive representative for the Colombian territory. Hoyos will be in charge of all Global Stem Cells Group divisions and programs in Colombia, including patient recruiting through Regenestem, physician training and certification trough Stem Cell Training, and stem cell equipment and disposables sales through Adimarket. Five dates are planned for training and physician certification under the Global Stem Cells Group brand in Colombia during 2015.

For more information, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Read the original post:
Maritza Novas, R.N., M.S.N and Alfredo Hoyos, M.D. to Speak at the EuroMedicom Aesthetic & Anti-Aging Medicine World ...

Posted in Stem Cells | Comments Off on Maritza Novas, R.N., M.S.N and Alfredo Hoyos, M.D. to Speak at the EuroMedicom Aesthetic & Anti-Aging Medicine World …

Page 1,963«..1020..1,9621,9631,9641,965..1,9701,980..»